Novavax Ships Millions of Updated COVID-19 Vaccine Doses
In a significant development, vaccine manufacturer Novavax Inc announced on Monday that it has successfully shipped millions of doses of its updated COVID-19 vaccine to distributors. This milestone follows the approval granted by U.S. regulators.
Last week, the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the updated vaccine in individuals aged 12 years and older. However, some batches of the vaccine required additional clearance from the FDA before they could be made available to the public.
Novavax is optimistic about the availability of these updated vaccine doses at U.S. pharmacies as early as this week.
The Maryland-based company, primarily known for its COVID vaccine, is currently implementing cost-cutting measures. It is banking on the commercial sales of its updated vaccine to ensure its financial stability. Novavax has explicitly stated that its financial health is at risk without this crucial development.
Unlike some of its mRNA-based competitors who saw substantial success during the pandemic, Novavax faced manufacturing issues that delayed its vaccine’s approval process when COVID-19 was at its peak.